Zedira Presents Clinical Candidate for Celiac Disease Therapy
In course of the Chicago celiac disease Conference preclinical data has been presented supporting the selection of Zedira’s novel Transglutaminase blocker ZED-101 as clinical candidate for the treatment of celiac disease.
Blocking tissue transglutaminase is a promising therapeutic option in celiac disease. Zedira developed rationally designed peptidomimetic blockers bearing a michael acceptor pharmacophore. The safety profile and selectivity over other transglutaminase isoenzymes make ZED-101 an optimal candidate for subsequent clinical development.
Zedira considers either out-licensing ZED-101 to a pharmaceutical company or further conducting preclinical and clinical trials backed by investors.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.